Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786601 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9L3MBTL1ALDH1A1SLC6A2 | |
| SCHEMBL1729143 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9L3MBTL1ALDH1A1SLC6A2 | |
| SCHEMBL1047240 | 0.84 | KCNK3 (0.47) | KCNK3KCNK9P2RY2P2RY1P2RY14 | |
| SCHEMBL1729802 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9L3MBTL1ALDH1A1SLC6A2 | |
| SCHEMBL5924730 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9P2RY2P2RY1P2RY14 | |
| SCHEMBL24779813 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9ARP2RY2P2RY1 | |
| SCHEMBL10192275 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9P2RY2P2RY1P2RY14 | |
| SCHEMBL1047239 | 0.84 | KCNK3 (0.47) | KCNK3KCNK9P2RY2P2RY1P2RY14 | |
| SCHEMBL21882592 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9L3MBTL1ALDH1A1SLC6A2 | |
| SCHEMBL10476125 | 0.84 | KCNK3 (0.43) | KCNK3KCNK9L3MBTL1ALDH1A1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059096-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230374230-A1 | CROSSLINKED GEL FORMULATION | ESSILOR INTERNATIONAL (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20230374230-A1 | CROSSLINKED GEL FORMULATION | ESSILOR INTERNATIONAL (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KCNK3 3909/4885KCNK9 2747/4885AR 1287/4885 |
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | KCNK3 1653/4885KCNK9 1272/4885AR 2775/4885 |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | KCNK3 642/4885KCNK9 669/4885AR 1267/4885 |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | KCNK3 999/4885KCNK9 1567/4885AR 444/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KCNK3 3909/4885KCNK9 2747/4885AR 1287/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KCNK3 3909/4885KCNK9 2747/4885AR 1287/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | KCNK3 1899/4885KCNK9 2101/4885AR 733/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | KCNK3 962/4885KCNK9 1450/4885AR 742/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | KCNK3 1410/4885KCNK9 1618/4885AR 3101/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | KCNK3 4269/4885KCNK9 3760/4885AR 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.